Abstract
Lymphomas are the third most common malignancy in children and adolescents and are among the most curable of childhood cancers with modern risk-adapted chemotherapy and radiation therapy. Despite significant improvements in outcomes, 10–15 % of children and adolescents either have disease that is refractory to primary therapy or relapse following an initial response. In both Hodgkin and non-Hodgkin lymphomas, hematopoietic stem cell transplantation (HCT) is an important therapeutic modality for the subset of patients with relapsed or refractory disease, although treatment approaches and outcomes vary significantly for different lymphoma subtypes and prognostic risk factors. Both autologous and allogeneic HCT are utilized in the setting of relapsed lymphomas, with salvage chemotherapy regimens and transplant strategies generally extrapolated from studies in adults due to a lack of pediatric-specific clinical trials. Research focused on optimization of salvage regimens and HCT strategies, as well as highly active novel agents, will be critical to further improving cure rates in pediatric lymphomas.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abali H, Urun Y, Oksuzoglu B, Budakoglu B, Yildirim N, Guler T, Ozet G, Zengin N (2008) Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 26(4):401–406. doi:10.1080/07357900701788098, 792702354 [pii]
Akhtar S, El Weshi A, Rahal M, Abdelsalam M, Al Husseini H, Maghfoor I (2010) High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 45(3):476–482. doi:10.1038/bmt.2009.197, bmt2009197 [pii]
Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak ML, Fuller D, Miller CB, Noga SJ, Fuchs E, Flinn IW, O'Donnell P, Seifter EJ, Mann RB, Jones RJ (2001) Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 19(23):4314–4321
Al Mahmoud R, Weitzman S, Schechter T, Ngan B, Abdelhaleem M, Alexander S (2012) Peripheral T-cell lymphoma in children and adolescents: a single-institution experience. J Pediatr Hematol Oncol 34(8):611–616. doi:10.1097/MPH.0b013e3182707592
Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, Malcovati L, Nascimbene C, Varettoni M, Volpini E, Klersy C, Bernasconi C (2000) Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 25(3):309–313. doi:10.1038/sj.bmt.1702154
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511. doi:10.1038/35000501
Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, Garcia-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Diez JL, Moraleda JM, Rubio-Felix D, Xicoy B, Martinez C, Mateos MV, Sierra J (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 12(2):172–183. doi:10.1016/j.bbmt.2005.09.009, S1083-8791(05)00673-7 [pii]
Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Korbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez HF, McLaughlin P, Cabanillas F, Champlin RE (2000) Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 26(6):615–620. doi:10.1038/sj.bmt.1702580
Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943–951. doi:10.1038/sj.bmt.1704942, 1704942 [pii]
Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE (2008) Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257–264. doi:10.3324/haematol.11828, haematol.11828 [pii]
Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE (2012) Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499–502. doi:10.3109/10428194.2011.615427
Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE et al (1993a) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 11(12):2342–2350
Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR, Coccia PF, Exelby PR, Siegel S, Meadows AT et al (1993b) Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 11(6):1024–1032
Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht C (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case–control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 17(1):222–229
Anselmo AP, Meloni G, Cavalieri E, Proia A, Enrici RM, Funaro D, Pescarmona E, Mandelli F (2000) Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Ann Hematol 79(2):79–82
Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A, Pastor M (1999) ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 10(5):593–595
Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ (2010) Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant 16(8):1145–1154. doi:10.1016/j.bbmt.2010.02.022, S1083-8791(10)00095-9 [pii]
Argiris A, Seropian S, Cooper DL (2000) High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 11(6):665–672
Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM (2011) Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 118(4):874–883. doi:10.1182/blood-2010-06-292615, blood-2010-06-292615 [pii]
Attarbaschi A, Dworzak M, Steiner M, Urban C, Fink FM, Reiter A, Gadner H, Mann G (2005) Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer 44(1):70–76. doi:10.1002/pbc.20121
Attarbaschi A, Mann G, Rosolen A, Williams D, Uyttebroeck A, Marky I, Lamant L, Horibe K, Wrobel G, Beishuizen A, Wossmann W, Reiter A, Mauguen A, Le Deley MC, Brugieres L (2011) Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma. Blood 117(21):5616–5619. doi:10.1182/blood-2010-12-324012, blood-2010-12-324012 [pii]
Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R, Crump M (2003) Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14(12):1762–1767
Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC, Vose JM, Armitage JO, Coccia PF, Bierman PJ (1999) Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 17(3):825–831
Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, Meijer CJ, Willemze R (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95(12):3653–3661
Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T (2008) Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 41(7):613–619. doi:10.1038/sj.bmt, 1705951. 1705951 [pii]
Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 23(15):3376–3382. doi:10.1200/JCO.2005.03.426, 23/15/3376 [pii]
Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave PB, Nademanee A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 105(11):4215–4222. doi:10.1182/blood-2005-01-0035, 2005-01-0035 [pii]
Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO (1993) High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 4(9):767–773
Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH (2008) Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 19(11):1935–1940. doi:10.1093/annonc/mdn404, mdn404 [pii]
Biswas T, Culakova E, Friedberg JW, Kelly JL, Dhakal S, Liesveld J, Phillips GL, Constine LS (2012) Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Radiother Oncol 103(3):367–72. doi:10.1016/j.radonc.2011.12.031, S0167-8140(12)00061-8 [pii]
Blum KA (2010) Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2010:93–100. doi:10.1182/asheducation-2010.1.93, 2010/1/93 [pii]
Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001) High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27(7):711–716. doi:10.1038/sj.bmt.1702867
Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease. J Exp Med 200(12):1623–1633. doi:10.1084/jem.20040890, jem.20040890 [pii]
Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G (1997) Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15(2):528–534
Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P, Bonadonna G (1998) Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 103(2):533–535
Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, Matteucci P, Grisanti S, Valagussa P, Bonadonna G, Gianni AM (2001) High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol Suppl 64:51–55
Brice P (2008) Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 141(1):3–13. doi:10.1111/j.1365-2141.2008.06998.x, BJH6998 [pii]
Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Ferme C (1996) Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 78(6):1293–1299, 10.1002/(SICI)1097-0142(19960915)78:6 < 1293::AID-CNCR18 > 3.0.CO;2-W [pii]
Brice P, Bouabdallah R, Moreau P, Divine M, Andre M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P (1997) Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 20(1):21–26. doi:10.1038/sj.bmt.1700838
Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, Pondarre C, Leverger G, Devalck C, Rodary C, Delsol G, Hartmann O (1998) CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92(10):3591–3598
Brugieres L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, Schmitt C, Landmann J, Patte C, Terrier-Lacombe MJ, Delsol G, Hartmann O (2000) Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children–a report from the French Society of Pediatric Oncology. Ann Oncol 11(1):53–58
Bureo E, Ortega JJ, Munoz A, Cubells J, Madero L, Verdaguer A, Baro J, Olive T, Maldonado MS, Pardo N et al (1995) Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 15(3):353–359
Burkhardt B (2009) Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? Br J Haematol 149(5):653–668. doi:10.1111/j.1365-2141.2009.08006.x, BJH8006 [pii]
Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A (2005) The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131(1):39–49. doi:10.1111/j.1365-2141.2005.05735.x, BJH5735 [pii]
Burkhardt B, Bruch J, Zimmermann M, Strauch K, Parwaresch R, Ludwig WD, Harder L, Schlegelberger B, Mueller F, Harbott J, Reiter A (2006a) Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 20(8):1422–1429. doi:10.1038/sj.leu.2404275, 2404275 [pii]
Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A (2006b) Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 24(3):491–499. doi:10.1200/JCO.2005.02.2707, 24/3/491 [pii]
Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, Zimmermann M, Strauch K, Ludwig WD, Schrappe M, Reiter A (2008) Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma 49(3):451–461. doi:10.1080/10428190701824551, 790280269 [pii]
Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A (2009) Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol 27(20):3363–3369. doi:10.1200/JCO.2008.19.3367, JCO.2008.19.3367 [pii]
Burkhardt B, Oschlies I, Klapper W, Zimmermann M, Woessmann W, Meinhardt A, Landmann E, Attarbaschi A, Niggli F, Schrappe M, Reiter A (2011) Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 25(1):153–160. doi:10.1038/leu.2010.245, leu2010245 [pii]
Burroughs LM et al (2008) Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 14(11):1279–1287
Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L, Vidriales B, del Canizo MC, Corral M, Gonzalez M, Leon A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF (1997) BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20(6):451–458. doi:10.1038/sj.bmt.1700913
Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH (2001) Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol 23(1):30–38
Cairo MS, Sposto R, Hoover-Regan M, Meadows AT, Anderson JR, Siegel SE, Kadin ME, Kjeldsberg CR, Wilson JF, Perkins SL, Lones MA, Morris E, Finlay JL (2003a) Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience. Am J Hematol 72(1):53–63. doi:10.1002/ajh.10262
Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR, Siegel SE, Lones MA, Tedeschi-Blok N, Kadin ME, Kjeldsberg CR, Wilson JF, Sanger W, Morris E, Krailo MD, Finlay JL (2003b) Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol 120(4):660–670, 4134 [pii]
Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109(7):2736–2743. doi:10.1182/blood-2006-07-036665, blood-2006-07-036665 [pii]
Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, Pinkerton R, Raphael M, McCarthy K, Perkins SL, Patte C (2012) Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol 30(4):387–393. doi:10.1200/JCO.2010.33.3369, JCO.2010.33.3369 [pii]
Castagna L, Sarina B, Todisco E, Magagnoli M, Balzarotti M, Bramanti S, Mazza R, Anastasia A, Bacigalupo A, Aversa F, Soligo D, Giordano L, Santoro A (2009) Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biol Blood Marrow Transplant 15(4):432–438. doi:10.1016/j.bbmt.2008.12.506, S1083-8791(08)01138-5 [pii]
Cesaro S, Pillon M, Visintin G, Putti MC, Gazzola MV, D'Amore E, Scarzello G, Zanesco L, Messina C, Rosolen A (2005) Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series. Eur J Haematol 75(1):22–26. doi:10.1111/j.1600-0609.2005.00422.x, EJH422 [pii]
Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, Forman SJ, Gopal AK (2012) Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119(26):6379–6381. doi:10.1182/blood-2012-03-418673, blood-2012-03-418673 [pii]
Cheson BD (2008) New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am 46(2):213–223. doi:10.1016/j.rcl.2008.03.003, vii. S0033-8389(08)00041-9 [pii]
Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81(5):1137–1145
Claviez A, Kabisch H, Suttorp M, Peters C, Hero B, Schiller I, Doerffel W, Schmitz N, Zintl F (2004a) The impact of disease status at transplant and time to first relapse on outcome in children and adolescents with Hodgkin's lymphoma undergoing autologous stem cell transplantation. ASH Annual Meeting Abstracts 104(11):1878
Claviez A, Klingebiel T, Beyer J, Nurnberger W, Ehninger G, Suttorp M, Dreger P, Dorffel W, Schmitz N (2004b) Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Ann Hematol 83(4):237–241. doi:10.1007/s00277-003-0814-y
Claviez A, Sureda A, Schmitz N (2008) Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 42(Suppl 2):S16–S24. doi:10.1038/bmt.2008.278, bmt2008278 [pii]
Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A, Mackinnon S, Slavin S, Dalle JH, Chacon MJ, Sarhan M, Wynn RF, Suttorp M, Dini G, Sureda A, Schmitz N (2009) Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 114(10):2060–2067. doi:10.1182/blood-2008-11-189399, blood-2008-11-189399 [pii]
Cocorocchio E, Peccatori F, Vanazzi A, Piperno G, Calabrese L, Botteri E, Travaini L, Preda L, Martinelli G (2012) High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Hematol Oncol 31(1):34–40. doi:10.1002/hon.2014
Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM (2009) Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol 27(9):1456–1461. doi:10.1200/JCO.2008.20.3778, JCO.2008.20.3778 [pii]
Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, van de Ven C, Perkins SL, Cairo MS (2007) A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Clin Cancer Res 13(18 Pt 2):5652s–5660s. doi:10.1158/1078-0432.CCR-07-1060, 13/18/5652s [pii]
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D (2009) Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10(2):147–156. doi:10.1016/S1470-2045(08)70314-0, S1470-2045(08)70314-0 [pii]
Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE (1988) Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. Blood 72(6):1891–1897
Crump M et al (1993) High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 11(4):704–711
Daw S, Wynn R, Wallace H (2011) Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol 152(3):249–260. doi:10.1111/j.1365-2141.2010.08455.x
de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R (2012) U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18(21):5845–9. doi:10.1158/1078-0432.CCR-12-1803. Epub 2012
Deffenbacher KE, Iqbal J, Sanger W, Shen Y, Lachel C, Liu Z, Liu Y, Lim MS, Perkins SL, Fu K, Smith L, Lynch J, Staudt LM, Rimsza LM, Jaffe E, Rosenwald A, Ott GK, Delabie J, Campo E, Gascoyne RD, Cairo MS, Weisenburger DD, Greiner TC, Gross TG, Chan WC (2012) Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 119(16):3757–3766. doi:10.1182/blood-2011-05-349662, blood-2011-05-349662 [pii]
Devetten MP et al (2009) Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 15(1):109–117
Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, Ivanov V, Schiano JM, Santoro A, Chabannon C, Balzarotti M, Blaise D, Bouabdallah R (2012) Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy. Haematologica 97(7):1073–9. doi:10.3324/haematol.2011.056051, haematol.2011.056051 [pii]
Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147(1):97–101. doi:10.1111/j.1365-2141.2009.07837.x, BJH7837 [pii]
Domm JA, Thompson M, Kuttesch JF, Acra S, Frangoul H (2005) Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature. J Pediatr Hematol Oncol 27(11):607–610, 00043426-200511000-00009 [pii]
Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP (2006) Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 106(3):616–622. doi:10.1002/cncr.21606
Dunleavy K, Pittaluga S, Janik J, Grant N, Shovlin M, Steinberg S, Raffeld M, Staudt L, Jaffe ES, Wilson WH (2006) Primary mediastinal large B-cell lymphoma (PMBL) outcome may be significantly improved by the addition of rituximab to dose-adjusted (DA)-EPOCH and obviates the need for radiation: results from a prospective study of 44 patients. ASH Annual Meeting Abstracts 108(11):209
Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH (2009a) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113(24):6069–6076. doi:10.1182/blood-2009-01-199679, blood-2009-01-199679 [pii]
Dunleavy K, Pittaluga S, Tay K, Grant N, Chen CC, Shovlin M, Steinberg S, Staudt LM, Jaffe ES, Janik JE, Wilson WH (2009b) Comparative clinical and biological features of primary mediastinal B-cell lymphoma (PMBL) and mediastinal grey zone lymphoma (MGZL). ASH Annual Meeting Abstracts 114(22):106
Dunleavy K, Grant C, Eberle FC, Pittaluga S, Jaffe ES, Wilson WH (2012) Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep 7(3):241–247. doi:10.1007/s11899-012-0130-5
Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP, Carroll WL, Camitta BM (2012) Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 30(22):2753–2759. doi:10.1200/JCO.2011.40.8724, JCO.2011.40.8724 [pii]
Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137(5):581–593, dst0039 [pii]
Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20(40):5623–5637. doi:10.1038/sj.onc.1204594
El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, Gaillard I, Divine M, Tabah-Fisch I, Reyes F, Haioun C (2007) Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18(8):1363–1368. doi:10.1093/annonc/mdm133, mdm133 [pii]
Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 103(10):2091–2098. doi:10.1002/cncr.20999
Falini B, Pileri S, De Solas I, Martelli MF, Mason DY, Delsol G, Gatter KC, Fagioli M (1990) Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 75(2):434–444
Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A (1999) ALK + lymphoma: clinico-pathological findings and outcome. Blood 93(8):2697–2706
Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A (2011) Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284–286. doi:10.1111/j.1365-2141.2011.08618.x
Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 20(2):467–475
Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A (2012) Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studies. Oncologist 17(8):1073–80. doi:10.1634/theoncologist.2012-0133, theoncologist.2012-0133 [pii]
Foyil KV, Bartlett NL (2012) Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J 18(5):450–456. doi:10.1097/PPO.0b013e31826aef4a, 00130404-201209000-00012 [pii]
Frankovich J, Donaldson SS, Lee Y, Wong RM, Amylon M, Verneris MR (2001) High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 7(1):49–57. doi:10.1053/bbmt.2001.v7.pm11215699, S1083-8791(01)50088-9 [pii]
Freed J, Kelly KM (2010) Current approaches to the management of pediatric Hodgkin lymphoma. Paediatr Drugs 12(2):85–98. doi:10.2165/11316170-000000000-00000, 2 [pii]
Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K (2004) Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 104(12):3797–3803. doi:10.1182/blood-2004-01-0231, 2004-01-0231 [pii]
Friedman DL, Wolden S, Constine L, Chen L, McCarten KM, Fitzgerald TJ, De Alarcon P, Chen AR, Hutchison R, Ehrlich P, Kobrinsky NL, Higman M, Hogan S, Roll L, Trippett T, Schwartz C (2010) AHOD0031: a phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: a report from the Children's Oncology Group. ASH Annual Meeting Abstracts 116(21):766
Fujita N, Mori T, Mitsui T, Inada H, Horibe K, Tsurusawa M (2008) The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer 51(2):188–192. doi:10.1002/pbc.21585
Fujita N, Kobayashi R, Takimoto T, Nakagawa A, Ueda K, Horibe K (2011) Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. Leuk Lymphoma 52(2):223–229. doi:10.3109/10428194.2010.537794
Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL Jr, Pavlovsky S, Peterson FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 14(2):572–578
Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364(8):775–776. doi:10.1056/NEJMc1013224
Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93(11):3913–3921
Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C (2008) Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 141(6):840–847. doi:10.1111/j.1365-2141.2008.07144.x, BJH7144 [pii]
Gerrard M, Waxman IM, Sposto R, Auperin A, Perkins SL, Goldman S, Harrison L, Pinkerton R, McCarthy K, Raphael M, Patte C, Cairo MS (2012) Outcome and pathological classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 121(2):278–85. doi:10.1182/blood-2012-04-422709, blood-2012-04-422709 [pii]
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Briere J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184–4190. doi:10.1200/JCO.2010.28.1618, JCO.2010.28.1618 [pii]
Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL (2003) Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21(19):3616–3622. doi:10.1200/JCO.2003.10.116, JCO.2003.10.116 [pii]
Goldberg JD, Chou JF, Horwitz S, Teruya-Feldstein J, Barker JN, Boulad F, Castro-Malaspina H, Giralt S, Jakubowski AA, Koehne G, van den Brink MR, Young JW, Zhang Z, Papadopoulos EB, Perales MA (2012) Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 53(6):1124–1129. doi:10.3109/10428194.2011.645818
Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS (2012) Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia 27(5):1174–7. doi:10.1038/leu.2012.255, leu2012255 [pii]
Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J (2008) Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol 26(32):5240–5247. doi:10.1200/JCO.2007.15.5507, JCO.2007.15.5507 [pii]
Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF, Appelbaum FR, Press OW (2007) High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 25(11):1396–1402. doi:10.1200/JCO.2006.09.1215, JCO.2006.09.1215 [pii]
Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120(3):560–568. doi:10.1182/blood-2011-12-397893, blood-2011-12-397893 [pii]
Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103(12):4429–4431. doi:10.1182/blood-2003-11-3883, 2003-11-3883 [pii]
Greaves P, Wilson A, Matthews J, Brown DL, Auer R, Montoto S, Lister TA, Gribben JG (2012) Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis. Br J Haematol 157(2):201–204. doi:10.1111/j.1365-2141.2011.08993.x
Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG (2009) A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 52(2):177–181. doi:10.1002/pbc.21753
Gross TG, Termuhlen AM (2008) Pediatric non-Hodgkin lymphoma. Curr Hematol Malig Rep 3(3):167–173. doi:10.1007/s11899-008-0024-8
Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M (2010) Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 16(2):223–230. doi:10.1016/j.bbmt.2009.09.021, S1083-8791(09)00444-3 [pii]
Guarini A, Minoia C, Giannoccaro M, Rana A, Iacobazzi A, Lapietra A, Raimondi A, Silvestris N, Gadaleta CD, Ranieri G (2012) mTOR as a target of everolimus in refractory/relapsed Hodgkin lymphoma. Curr Med Chem 19(7):945–954, BSP/CMC/E-Pub/2012/083 [pii]
Guilcher GM, Rizzuti FA, Lewis VA, Stewart DA (2012) Single-agent high-dose melphalan followed by auto-SCT for relapsed and refractory Hodgkin lymphoma in children and adolescents. Bone Marrow Transplant 47(3):395–398. doi:10.1038/bmt.2011.97, bmt201197 [pii]
Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 18(21):3633–3642
Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24(19):3121–3127. doi:10.1200/JCO.2005.05.1003, [pii]
Haddley K (2012) Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma. Drugs Today (Barc) 48(4):259–270. doi:10.1358/dot.2012.48.4.1788435, 1788435 [pii]
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282. doi:10.1182/blood-2003-05-1545, [pii]
Harris RE, Termuhlen AM, Smith LM, Lynch J, Henry MM, Perkins SL, Gross TG, Warkentin P, Vlachos A, Harrison L, Cairo MS (2011) Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 17(2):249–258. doi:10.1016/j.bbmt.2010.07.002, S1083-8791(10)00292-2 [pii]
Hoppe BS, Flampouri S, Lynch J, Slayton W, Zaiden R, Li Z, Mendenhall NP (2012) Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. Oncology (Williston Park) 26(5):456–459, 462–455
Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 89(3):801–813
Horton TM, Drachtman RA, Chen L, Trippett TM, DeAlarcon P, Chen AR, Guillerman R, McCarten K, Hogan SM, Schwartz CL (2010) A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin disease (HD): A Children's Oncology Group (COG) study. J Clin Oncol (15s):Abstract 9537
Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2012) SEER Cancer Statistics Review 1975–2009 (Vintage 2009 Populations). http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012. National Cancer Institute, Bethesda
Hutchison RE, Laver JH, Chang M, Muzzafar T, Desai S, Murphy S, Schwenn M, Shuster J, Link MP (2008) Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study. Pediatr Blood Cancer 51(1):29–33. doi:10.1002/pbc.21543
Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L (2007) Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481–2489. doi:10.1002/cncr.22714
Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, Armand P, Alyea EP, Freedman AS, Soiffer RJ, Antin JH (2011) A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 22(7):1608–1613. doi:10.1093/annonc/mdq698, mdq698 [pii]
Jaffe ES (2006) Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program, 317–322. doi:10.1182/asheducation-2006.1.317. 2006/1/317 [pii]
James ND, Kingston JE, Plowman PN, Meller S, Pinkerton R, Barrett A, Sandland R, McElwain TJ, Malpas JS (1992) Outcome of children with resistant and relapsed Hodgkin's disease. Br J Cancer 66(6):1155–1158
Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, Grant N, Gutierrez M, Waldmann TA, Wilson WH (2004) Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 104(10):3355–3357. doi:10.1182/blood-2003-11-3922, 2003-11-3922 [pii]
Jantunen E, Kuittinen T, Nousiainen T (2003) BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 44(7):1151–1158. doi:10.1080/1042819031000083028
Jermann M, Jost LM, Taverna C, Jacky E, Honegger HP, Betticher DC, Egli F, Kroner T, Stahel RA (2004) Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 15(3):511–516
Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C (2008) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 87(1):43–48. doi:10.1007/s00277-007-0360-0
Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE (2010) A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 85(5):320–324. doi:10.1002/ajh.21664
Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77(3):649–653
Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96(4):1280–1286
Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A (2002a) New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 20(1):221–230
Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK, Diehl V, Engert A (2002b) Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 13(10):1628–1635
Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dorken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A (2005) High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 16(8):1359–1365. doi:10.1093/annonc/mdi248, mdi248 [pii]
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578. doi:10.1200/JCO.2006.08.2305, JCO.2006.08.2305 [pii]
Kahn S, Flowers C, Xu Z, Esiashvili N (2011) Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 81(1):175–180. doi:10.1016/j.ijrobp.2010.05.010, S0360-3016(10)00684-X [pii]
Kaneko Y, Frizzera G, Edamura S, Maseki N, Sakurai M, Komada Y, Tanaka H, Sasaki M, Suchi T et al (1989) A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 73(3):806–813
Keller FG, Castellino SM, Nachman JB (2009) What is the best treatment for children with limited-stage Hodgkin lymphoma? Curr Hematol Malig Rep 4(3):129–135. doi:10.1007/s11899-009-0019-0
Kelly KM (2011) Management of children with high-risk Hodgkin lymphoma. Br J Haematol 157(1):3–13. doi:10.1111/j.1365-2141.2011.08975.x
Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S, Lones M, Villaluna D, Weiner M (2011) BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 117(9):2596–2603. doi:10.1182/blood-2010-05-285379, blood-2010-05-285379 [pii]
Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S, Uchida T, Kishi K, Tanaka Y, Kohno A, Kasai M, Higuchi M, Mori S, Fukuda T, Izutsu K, Sao H, Ishikawa T, Ichinohe T, Takeuchi K, Tajima K, Tanosaki R, Harada M, Taniguchi S, Tobinai K, Hotta T, Takaue Y (2006) Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108(1):382–389. doi:10.1182/blood-2005-02-0596, 2005-02-0596 [pii]
Kobayashi R, Yamato K, Tanaka F, Takashima Y, Inada H, Kikuchi A, Kumagai MA, Sunami S, Nakagawa A, Fukano R, Fujita N, Mitsui T, Tsurusawa M, Mori T (2010) Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer 54(2):212–215. doi:10.1002/pbc.22329
Kobrinsky NL et al (2001) Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 19(9):2390–2396
Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ (2008) Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 26(1):90–95. doi:10.1200/JCO.2007.11.9248, JCO.2007.11.9248 [pii]
Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES (2005) Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol 8(1):52–60. doi:10.1007/s10024-004-8087-6
Kung FH, Harris MB, Krischer JP (1999) Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study. Med Pediatr Oncol 32(3):225–226
Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106(2):353–360. doi:10.1002/cncr.21587
Kuruvilla J, Keating A, Crump M (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood 117(16):4208–4217. doi:10.1182/blood-2010-09-288373, blood-2010-09-288373 [pii]
Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26(2):218–224. doi:10.1200/JCO.2007.12.6219, 26/2/218 [pii]
Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, Novitzky N, Goldstone AH, Sureda A, Schmitz N (2009) Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27(24):3951–3958. doi:10.1200/JCO.2008.20.4628, JCO.2008.20.4628 [pii]
Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T (1997) High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 90(8):2921–2930
Lamant L, McCarthy K, d’Amore E, Klapper W, Nakagawa A, Fraga M, Maldyk J, Simonitsch-Klupp I, Oschlies I, Delsol G, Mauguen A, Brugieres L, Le Deley MC (2011) Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol 29(35):4669–4676. doi:10.1200/JCO.2011.36.5411
Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, Muhs A, Duerst RE, Abboud CN, Packman CH, DiPersio JF, Constine LS, Rowe JM, Liesveld JL (1998) Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 22(3):265–271. doi:10.1038/sj.bmt.1701325
Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB (2005) Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 23(3):541–547. doi:10.1200/JCO.2005.11.075, 23/3/541 [pii]
Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN (2010) A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 16(1):35–45. doi:10.1016/j.bbmt.2009.08.011, S1083-8791(09)00387-5 [pii]
Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, Kadin ME, Vardiman JW (1989) The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 3(12):866–870
Le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I, McCarthy K, Zimmermann M, Brugieres L (2008) Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood 111(3):1560–1566. doi:10.1182/blood-2007-07-100958, blood-2007-07-100958 [pii]
Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugieres L (2010) Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 28(25):3987–3993. doi:10.1200/JCO.2010.28.5999, JCO.2010.28.5999 [pii]
Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26(14):2264–2271. doi:10.1200/JCO.2007.14.1366, JCO.2007.14.1366 [pii]
Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, Ji Y, Younes A (2012) The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 119(17):4017–4025. doi:10.1182/blood-2011-01-331421, blood-2011-01-331421 [pii]
Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101(7):2476–2482. doi:10.1182/blood-2002-05-1483, 2002-05-1483 [pii]
Liang X, Meech SJ, Odom LF, Bitter MA, Ryder JW, Hunger SP, Lovell MA, Meltesen L, Wei Q, Williams SA, Hutchinson RN, McGavran L (2004) Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK + anaplastic large cell lymphoma. Am J Clin Pathol 121(4):496–506. doi:10.1309/TLE8-FN6E-YF0N-JGP7
Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, Agarwal R (2004) High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 22(22):4532–4540. doi:10.1200/JCO.2004.02.121, 22/22/4532 [pii]
Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341(8852):1051–1054
Loiseau HA, Hartmann O, Valteau D, McDowell H, Brugieres L, Vassal G, Kalifa C, Patte C, Lemerle J (1991) High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 8(6):465–472
Lones MA, Cairo MS, Perkins SL (2000a) T-cell-rich large B-cell lymphoma in children and adolescents: a clinicopathologic report of six cases from the Children's Cancer Group Study CCG-5961. Cancer 88(10):2378–2386, 10.1002/(SICI)1097-0142(20000515)88:10 < 2378::AID-CNCR24 > 3.0.CO;2-Q [pii]
Lones MA, Perkins SL, Sposto R, Kadin ME, Kjeldsberg CR, Wilson JF, Cairo MS (2000b) Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol 18(22):3845–3853
Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT Jr (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10(2):210–218
Lopez A, Gutierrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perello A, Alarcon J, Martinez J, Rodriguez J (2008) GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 80(2):127–132. doi:10.1111/j.1600-0609.2007.00996.x, EJH996 [pii]
Lorsbach RB, Shay-Seymore D, Moore J, Banks PM, Hasserjian RP, Sandlund JT, Behm FG (2002) Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 99(6):1959–1964
Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL, Tibshirani R, Levy R (2001) Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98(4):945–951
Magagnoli M, Sarina B, Balzarotti M, Castagna L, Timofeeva I, Nozza A, Bertuzzi A, Siracusano L, Sinnone M, Santoro A (2001) Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 28(10):923–927. doi:10.1038/sj.bmt.1703265
Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A (2007) IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant 40(11):1019–1025. doi:10.1038/sj.bmt.1705862, 1705862 [pii]
Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 12(10):1065–1072. doi:10.1016/j.bbmt.2006.06.006, S1083-8791(06)00420-4 [pii]
Martin A, Fernandez-Jimenez MC, Caballero MD, Canales MA, Perez-Simon JA, Garcia de Bustos J, Vazquez L, Hernandez-Navarro F, San Miguel JF (2001) Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 113(1):161–171, bjh2714 [pii]
Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, Garcia-Sanchez P, Vazquez L, Nistal S, Requena MJ, Donato EM, Gonzalez JA, Leon A, Ruiz C, Grande C, Gonzalez-Barca E, Caballero MD (2008) R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 93(12):1829–1836. doi:10.3324/haematol.13440, haematol.13440 [pii]
Mauz-Korholz C, Hasenclever D, Dorffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlen J, Bergstrasser E, Fossa A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Korholz D (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28(23):3680–3686. doi:10.1200/JCO.2009.26.9381, JCO.2009.26.9381 [pii]
Mehta N, Wayne AS, Kim YH, Hale GA, Alvarado CS, Myskowski P, Jaffe ES, Busam KJ, Pulitzer M, Zwerner J, Horwitz S (2012) Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk 12(1):20–25. doi:10.1016/j.clml.2011.06.016, S2152-2650(11)00270-9 [pii]
Metzger ML, Hudson MM, Krasin MJ, Wu J, Kaste SC, Kun LE, Sandlund JT, Howard SC (2010) Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer 116(18):4376–4384. doi:10.1002/cncr.25225
Metzger M, Billett A, Friedmann AM, Krasin MJ, Howard SC, Weinstein HJ, Larsen E, Marcus KC, Billups C, Wu J, Donaldson SS, Link MP, Hudson MM (2012) Stanford V chemotherapy and involved field radiotherapy for children and adolescents with unfavorable risk Hodgkin lymphoma: Results of a multi-institutional prospective clinical trial. ASCO Meeting Abstracts 30 (15 suppl):9502
Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, Sposto R, Davenport V, Cairo MS, Perkins SL (2008) Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer 51(3):369–374. doi:10.1002/pbc.21619
Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14(4):1291–1296
Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M (2009) Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer 52(5):591–595. doi:10.1002/pbc.21941
Moore S, Kayani I, Peggs K, Qian W, Lowry L, Thomson K, Linch DC, Ardeshna K (2012) Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. Br J Haematol 157(5):543–52. doi:10.1111/j.1365-2141.2012.09096.x
Mora J, Filippa DA, Thaler HT, Polyak T, Cranor ML, Wollner N (2000) Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer 88(1):186–197, 10.1002/(SICI)1097-0142(20000101)88:1 < 186::AID-CNCR26 > 3.0.CO;2–5 [pii]
Mora J, Filippa DA, Qin J, Wollner N (2003) Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 98(6):1283–1291. doi:10.1002/cncr.11615
Mori T, Takimoto T, Katano N, Kikuchi A, Tabuchi K, Kobayashi R, Ayukawa H, Kumagai MA, Horibe K, Tsurusawa M (2006) Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol 132(5):594–597. doi:10.1111/j.1365-2141.2005.05910.x, BJH5910 [pii]
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263(5151):1281–1284
Moskowitz C (2004) An update on the management of relapsed and primary refractory Hodgkin's disease. Semin Oncol 31(2 Suppl 4):54–59, S0093775404000752 [pii]
Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17(12):3776–3785
Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97(3):616–623
Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124(5):645–652, 4828 [pii]
Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, Moskowitz CH (2010a) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116(23):4934–4937. doi:10.1182/blood-2010-05-282756, blood-2010-05-282756 [pii]
Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, Kewalramani T, Moskowitz AJ, Rice RD, Maragulia J, Vanak J, Trippett T, Hamlin P, Horowitz S, Noy A, O'Connor OA, Portlock C, Straus D, Nimer SD (2010b) High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 148(6):890–897. doi:10.1111/j.1365-2141.2009.08037.x, BJH8037 [pii]
Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, Horwitz S, Moskowitz AJ, Noy A, Palomba L, Perales MA, Portlock C, Straus D, Maragulia JC, Schoder H, Yahalom J (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119(7):1665–1670. doi:10.1182/blood-2011-10-388058, blood-2011-10-388058 [pii]
Motabi IH, Dipersio JF (2012) Advances in stem cell mobilization. Blood Rev 26(6):267–278. doi:10.1016/j.blre.2012.09.003, S0268-960X(12)00063-X [pii]
Mounier N, Gisselbrecht C, Briere J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F (2004) All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 15(12):1790–1797. doi:10.1093/annonc/mdh471, 15/12/1790 [pii]
Mundt AJ, Sibley G, Williams S, Hallahan D, Nautiyal J, Weichselbaum RR (1995) Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 33(2):261–270, 0360301695001807 [pii]
Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A (2010) Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 45(7):1147–1153. doi:10.1038/bmt.2009.318, bmt2009318 [pii]
Nachman J (2009) Allotransplantation in pediatric HL. Blood 114(10):2008–2009. doi:10.1182/blood-2009-07-228973, 114/10/2008 [pii]
Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G et al (1995) High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 85(5):1381–1390
Neth O, Seidemann K, Jansen P, Mann G, Tiemann M, Ludwig WD, Riehm H, Reiter A (2000) Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 35(1):20–27. doi:10.1002/1096-911X(200007)35:1<20::AID-MPO4>3.0.CO;2-L [pii]
Nieto Y, Thall PF, Andersson BS, Popat UR, Anderlini P, Valdez BC, Shpall EJ, Qazilbash M, Alousi AM, Chancoco C, Hosing CM, Kebriaei P, Bashir Q, Shah N, Khouri I, Ciurea SO, McMullin B, Rondon G, Champlin R, Jones R (2011) High-dose infusional gemcitabine (Gem) combined with busulfan (Bu) and melphalan (Mel) (GemBuMel) with autologous stem-cell transplant (ASCT) in patients with refractory lymphoid malignancies. ASH Annual Meeting Abstracts 118(21):3083
Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, Takase K, Henzan H, Kato K, Takenaka K, Fukuda T, Harada N, Nagafuji K, Teshima T, Akashi K, Harada M, Eto T (2010) Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 45(2):311–316. doi:10.1038/bmt.2009.165, bmt2009165 [pii]
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182–1189. doi:10.1200/JCO.2010.29.9024, JCO.2010.29.9024 [pii]
Ohshima K, Kawasaki C, Muta H, Muta K, Deyev V, Haraoka S, Suzumiya J, Podack ER, Kikuchi M (2001) CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 39(2):156–162, his1196 [pii]
Oki Y, Copeland A, Younes A (2011) Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 4(3):245–252. doi:10.1586/ehm.11.24
O'leary M, Sheaffer J, Keller F, Shu X-O, Cheson BD (2006) Lymphomas and reticuloendothelial neoplasms. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. National Cancer Institute, Bethesda, NIH Pub. No. 06-5767
Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, Morris SW, Kennedy W, Jones SC, Sandlund JT (2003) ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 102(7):2642–2644. doi:10.1182/blood-2003-04-1095, 2003-04-1095 [pii]
Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B, Harder L, Siebert R, Reiter A, Parwaresch R (2006) Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 107(10):4047–4052. doi:10.1182/blood-2005-10-4213, 2005-10-4213 [pii]
Oschlies I, Burkhardt B, Salaverria I, Rosenwald A, d’Amore ES, Szczepanowski M, Koch K, Hansmann ML, Stein H, Moller P, Reiter A, Zimmermann M, Rosolen A, Siebert R, Jaffe ES, Klapper W (2011) Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 96(2):262–268. doi:10.3324/haematol.2010.030809, haematol.2010.030809 [pii]
Panobinostat shows efficacy in Hodgkin lymphoma (2012) Cancer Discov 2 (6):OF8. doi:10.1158/2159-8290.CD-RW2012-064. 2159–8290.CD-RW2012-064 [pii]
Patel JL, Smith LM, Anderson J, Abromowitch M, Campana D, Jacobsen J, Lones MA, Gross TG, Cairo MS, Perkins SL (2012) The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report. Br J Haematol 159(4):454–461. doi:10.1111/bjh.12042
Patte C, Philip T, Rodary C, Bernard A, Zucker JM, Bernard JL, Robert A, Rialland X, Benz-Lemoine E, Demeocq F et al (1986) Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4(8):1219–1226
Patte C, Philip T, Rodary C, Zucker JM, Behrendt H, Gentet JC, Lamagnere JP, Otten J, Dufillot D, Pein F et al (1991) High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9(1):123–132
Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphael M, Terrier-Lacombe MJ (2001) The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97(11):3370–3379
Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109(7):2773–2780. doi:10.1182/blood-2006-07-036673, blood-2006-07-036673 [pii]
Patti C, Majolino I, Scime R, Indovina A, Vasta S, Liberti G, Gentile S, Santoro A, Pisa R, Caronia F (1993) High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. Eur J Haematol 51(1):18–24
Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, Craddock C, Pettengell R, Dogan A, Thomson KJ, Morris EC, Hale G, Waldmann H, Goldstone AH, Linch DC, Mackinnon S (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365(9475):1934–1941. doi:10.1016/S0140-6736(05)66659-7, S0140-6736(05)66659-7 [pii]
Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S (2007) Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 139(1):70–80. doi:10.1111/j.1365-2141.2007.06759.x, BJH6759 [pii]
Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, Santini G, Blaise D, Greinix H, Ferrant A, Cornelissen J, Schmitz N, Goldstone AH (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31(8):667–678. doi:10.1038/sj.bmt.1703891, 1703891 [pii]
Pezner RD, Nademanee A, Niland JC, Vora N, Forman SJ (1995) Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. Radiother Oncol 34(1):23–29, 016781409401502T [pii]
Pfreundschuh MG et al (1994) Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12(3):580–586
Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391. doi:10.1016/S1470-2045(06)70664-7, S1470-2045(06)70664-7 [pii]
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333(23):1540–1545. doi:10.1056/NEJM199512073332305
Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW et al (1989) Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73(8):2086–2092
Poen JC, Hoppe RT, Horning SJ (1996) High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 36(1):3–12, S0360301696002775 [pii]
Poirel HA, Cairo MS, Heerema NA, Swansbury J, Auperin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphael M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C (2009) Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia 23(2):323–331. doi:10.1038/leu.2008.312, leu2008312 [pii]
Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE (2004) Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33(10):1015–1023. doi:10.1038/sj.bmt.1704483, 1704483 [pii]
Prete A et al (2005) High dose therapy (HDCT) and autologous haematopoietic stem cell transplantation (aSCT) in paediatric patients with recurrent or refractory Hodgkin's disease (HD): results and outcome. ASH Annual Meeting Abstracts 106(11):2088
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190–2196. doi:10.1200/JCO.2011.38.0402, JCO.2011.38.0402 [pii]
Puig N, de la Rubia J, Remigia MJ, Jarque I, Martin G, Cupelli L, Sanz GF, Lorenzo I, Sanz J, Martinez JA, Jimenez C, Sanz MA (2006) Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 47(8):1488–1494. doi:10.1080/10428190500527769, X7L0307307456J73 [pii]
Puig N, Pintilie M, Seshadri T, al-Farsi K, Franke N, Keating A, Kuruvilla J, Crump M (2011) High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. Bone Marrow Transplant 46(10):1339–1344. doi:10.1038/bmt.2010.294, bmt2010294 [pii]
Quintanilla-Martinez L, de Jong D, de Mascarel A, Hsi ED, Kluin P, Natkunam Y, Parrens M, Pileri S, Ott G (2009) Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematop 2(4):211–236. doi:10.1007/s12308-009-0053-9
Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, Min DJ (2006) Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 47(2):130–140. doi:10.1002/pbc.20550
Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M, Haghighinejad H (2012) Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant 10(2):163–167
Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF et al (1991) Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9(10):1871–1879
Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ et al (1994) Intensive therapy with cyclophosphamide, carmustine, etoposide +/− cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83(5):1193–1199
Reece DE et al (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/− P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86(2):451–456
Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Muller-Hermelink HK, Wilhelm M (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106–113. doi:10.1200/JCO.2008.17.4870, JCO.2008.17.4870 [pii]
Reiter A, Klapper W (2008) Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol 142(3):329–347. doi:10.1111/j.1365-2141.2008.06988.x, BJH6988 [pii]
Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, Niemeyer CM, Gadner H, Muller-Weihrich S, Ritter J et al (1992) Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood 80(10):2471–2478
Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, Sykora KW, Ludwig WD, Gadner H, Riehm H (1995) Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage–a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 13(2):359–372
Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Muller-Weihrich S, Pluss HJ, Zintl F, Henze G, Riehm H (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 94(10):3294–3306
Rimokh R, Magaud JP, Berger F, Samarut J, Coiffier B, Germain D, Mason DY (1989) A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). Br J Haematol 71(1):31–36
Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, Taghipour G, Schmitz N (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100(13):4310–4316. doi:10.1182/blood-2001-11-0107, 2001-11-0107 [pii]
Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, Iriondo A, Cook G, Pettitt A, Socie G, Bonifazi F, Bosi A, Michallet M, Liakopoulou E, Maertens J, Passweg J, Clarke F, Martino R, Schmitz N (2009) Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 94(2):230–238. doi:10.3324/haematol.13441, haematol.13441 [pii]
Rosolen A, Pillon M, Garaventa A, Burnelli R, d’Amore ES, Giuliano M, Comis M, Cesaro S, Tettoni K, Moleti ML, Tamaro P, Visintin G, Zanesco L (2005) Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 104(10):2133–2140. doi:10.1002/cncr.21438
Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A (2007) Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol 25(25):3915–3922. doi:10.1200/JCO.2007.11.0700, 25/25/3915 [pii]
Sandlund JT, Pui CH, Roberts WM, Santana VM, Morris SW, Berard CW, Hutchison RE, Ribeiro RC, Mahmoud H, Crist WM et al (1994) Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 84(8):2467–2471
Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin's lymphoma in childhood. N Engl J Med 334(19):1238–1248. doi:10.1056/NEJM199605093341906
Sandlund JT, Bowman L, Heslop HE, Krance R, Mahmoud H, Pui CH, Hale G, Benaim E (2002) Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy 4(3):253–258. doi:10.1080/146532402320219763
Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, Hijiya N, Campana D, Hudson MM, Ribeiro RC (2009) Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia 23(6):1127–1130. doi:10.1038/leu.2008.400, leu2008400 [pii]
Sandlund JT, Pui CH, Mahmoud H, Zhou Y, Lowe E, Kaste S, Kun LE, Krasin MJ, Onciu M, Behm FG, Ribeiro RC, Razzouk BI, Howard SC, Metzger ML, Hale GA, Rencher R, Graham K, Hudson MM (2011) Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol 22(2):468–471. doi:10.1093/annonc/mdq348, mdq348 [pii]
Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 18(13):2615–2619
Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 92(1):35–41
Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, Falda M, Guidi S, Ciceri F, Bonini A, Ferrari S, Malagola M, Morello E, Milone G, Bruno B, Mordini N, Viviani S, Levis A, Giordano L, Santoro A, Corradini P (2010) Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 115(18):3671–3677. doi:10.1182/blood-2009-12-253856, blood-2009-12-253856 [pii]
Savage KJ (2006) Primary mediastinal large B-cell lymphoma. Oncologist 11(5):488–495. doi:10.1634/theoncologist.11-5-488, 11/5/488 [pii]
Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15(10):1467–1475. doi:10.1093/annonc/mdh392, 15/10/1467 [pii]
Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 17(1):123–130. doi:10.1093/annonc/mdj030, mdj030 [pii]
Schellong G, Dorffel W, Claviez A, Korholz D, Mann G, Scheel-Walter HG, Bokkerink JP, Riepenhausen M, Luders H, Potter R, Ruhl U, DAL/GPOH (2005) Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 23(25):6181–6189. doi:10.1200/JCO.2005.07.930
Schmitz N, Glass B, Dreger P, Haferlach T, Horst HA, Ollech-Chwoyka J, Suttorp M, Gassmann W, Loffler H (1993) High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol 66(5):251–256
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359(9323):2065–2071. doi:10.1016/S0140-6736(02)08938-9, S0140-6736(02)08938-9 [pii]
Schmitz N, Haverkamp H, Josting A, Diehl V, Pfistner B, Carella AM, Haenel M, Boissevain F, Bokemeyer C, Goldstone AH (2005) Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). ASCO Meeting Abstracts 23 (16 suppl):6508
Schutt P, Passon J, Ebeling P, Welt A, Muller S, Metz K, Moritz T, Seeber S, Nowrousian MR (2007) Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol 78(2):93–101. doi:10.1111/j.1600-0609.2006.00796.x, EJH796 [pii]
Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, Dorffel W, Zimmermann M, Mann G, Gadner H, Parwaresch R, Riehm H, Reiter A (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97(12):3699–3706
Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K, Schrappe M, Zimmermann M, Niemeyer C, Parwaresch R, Riehm H, Reiter A (2003) Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol 21(9):1782–1789. doi:10.1200/JCO.2003.08.151, JCO.2003.08.151 [pii]
Setty BA, Termuhlen AM (2010) Rare pediatric non-hodgkin lymphoma. Curr Hematol Malig Rep 5(3):163–168. doi:10.1007/s11899-010-0055-9
Shankar AG, Ashley S, Radford M, Barrett A, Wright D, Pinkerton CR (1997) Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group. J Clin Oncol 15(7):2622–2630
Sieniawski M, Franklin J, Nogova L, Glossmann JP, Schober T, Nisters-Backes H, Diehl V, Josting A (2007) Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 25(15):2000–2005. doi:10.1200/JCO.2006.10.1386, JCO.2006.10.1386 [pii]
Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A (2008) Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 19(7):1312–1319. doi:10.1093/annonc/mdn052, mdn052 [pii]
Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P (2008) Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 14(8):904–912. doi:10.1016/j.bbmt.2008.05.021, S1083-8791(08)00240-1 [pii]
Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28(15):2625–2634. doi:10.1200/JCO.2009.27.0421, JCO.2009.27.0421 [pii]
Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, Thomas J, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102(1):53–59. doi:10.1182/blood-2002-12-3842, 2002-12-3842 [pii]
Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362(10):875–885. doi:10.1056/NEJMoa0905680, 362/10/875 [pii]
Steidl C, Connors JM, Gascoyne RD (2011) Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 29(14):1812–1826. doi:10.1200/JCO.2010.32.8401, JCO.2010.32.8401 [pii]
Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H et al (1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66(4):848–858
Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96(12):3681–3695
Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI (2003) The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 9(8):529–539, S1083879103002052 [pii]
Stockklausner C, Behnisch W, Mechtersheimer G, Moller P, Kulozik AE (2008) Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide. Pediatr Blood Cancer 50(1):126–129. doi:10.1002/pbc.20838
Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG (2004) Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 26(11):740–745, 00043426-200411000-00010 [pii]
Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J, Jarque I, Caballero MD, Ferra C, Lopez A, Garcia-Larana J, Cabrera R, Carrera D, Ruiz-Romero MD, Leon A, Rifon J, Diaz-Mediavilla J, Mataix R, Morey M, Moraleda JM, Altes A, Lopez-Guillermo A, de la Serna J, Fernandez-Ranada JM, Sierra J, Conde E (2001) Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 19(5):1395–1404
Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N (2008) Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26(3):455–462. doi:10.1200/JCO.2007.13.2415, JCO.2007.13.2415 [pii]
Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcarcel D, Besalduch J, Duarte R, Leon A, Pascual MJ, Garcia-Noblejas A, Lopez Corral L, Xicoy B, Sierra J, Schmitz N (2012) Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97(2):310–317. doi:10.3324/haematol.2011.045757, haematol.2011.045757 [pii]
Suyani E, Sucak GT, Aki SZ, Yegin ZA, Ozkurt ZN, Yagci M (2011) Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 90(6):685–691. doi:10.1007/s00277-010-1113-z
Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, Linch DC, Schmitz N, Goldstone AH (1999) High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17(10):3101–3109
Tang T, Tay K, Quek R, Tao M, Tan SY, Tan L, Lim ST (2010) Peripheral T-cell lymphoma: review and updates of current management strategies. Adv Hematol 2010:624040. doi:10.1155/2010/624040
Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A (2003) High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 97(11):2748–2759. doi:10.1002/cncr.11414
Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79(24):7837–7841
Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, Gross TG, Abromowitch M (2012) Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group. Pediatr Blood Cancer 59(7):1229–1233. doi:10.1002/pbc.24149
Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, Pettengell R, Milligan D, Morris EC, Goldstone AH, Linch DC, Mackinnon S (2008) Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 41(9):765–770. doi:10.1038/sj.bmt.1705977, 1705977 [pii]
Trippett T, De Alarcon P, London W, Sposto R, Chen A, Gardner S, Schwartz C (2004) AHOD00P1, a Pilot Study of Re-Induction Chemotherapy with Ifosfamide, and Vinorelbine (IV) in Children with Refractory/Relapsed Hodgkin Disease. ASH Annual Meeting Abstracts 104(11):2496
Tsang RW, Gospodarowicz MK, Sutcliffe SB, Crump M, Keating A (1999) Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group. Eur J Cancer 35(1):73–78, S0959804998003049 [pii]
Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cave H, Baila L, Bertrand Y (2008) Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer 44(6):840–846. doi:10.1016/j.ejca.2008.02.011, S0959-8049(08)00120-2 [pii]
Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS (2005) Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 44(4):338–347. doi:10.1002/pbc.20227
Varterasian M, Ratanatharathorn V, Uberti JP, Karanes C, Abella E, Momin F, Kasten-Sportes C, Al-Katib A, Lum L, Heilbrun LK et al (1995) Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Leuk Lymphoma 20(1–2):59–65. doi:10.3109/10428199509054754
Vecchi V, Burnelli R, Pileri S, Rosito P, Sabattini E, Civino A, Pericoli R, Paolucci G (1993) Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. Med Pediatr Oncol 21(6):402–410
Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L (2004) Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 5(2):110–115
Verdeguer A et al (2000) Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 25(1):31–34
Villa D, Seshadri T, Puig N, Massey C, Tsang R, Keating A, Crump M, Kuruvilla J (2011) Second line salvage chemotherapy for transplant-eligible patients with Hodgkin lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica 97(5):751–7. doi:10.3324/haematol.2011.047670, haematol.2011.047670 [pii]
Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 118(12):3419–3425. doi:10.1182/blood-2011-04-351924, blood-2011-04-351924 [pii]
Vitolo U, Barosi G, Fanti S, Gianni AM, Martelli M, Petrini M, Zinzani PL, Tura S (2010) Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. Am J Hematol 85(2):147–155. doi:10.1002/ajh.21602
Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM (2010) Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma 51(7):1251–1259. doi:10.3109/10428194.2010.486090
Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, Frappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80(8):2142–2148
Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, Horwitz SM (2012) Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 13(1):8–14. doi:10.1016/j.clml.2012.09.002, S2152-2650(12)00162-0 [pii]
Wadhwa P, Shina DC, Schenkein D, Lazarus HM (2002) Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation? Bone Marrow Transplant 29(3):183–189. doi:10.1038/sj.bmt.1703367
Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR (2012) Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 53(11):2283–6. doi:10.3109/10428194.2012.676170
Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E (2004) High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 34(7):581–587. doi:10.1038/sj.bmt.1704637, 1704637 [pii]
Wendland MM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK (2006) The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol 29(2):189–195. doi:10.1097/01.coc.0000209370.61355.8e, 00000421-200604000-00017 [pii]
Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A, Meloni G (1993) Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 11(11):2243–2249
Wimmer RS, Chauvenet AR, London WB, Villaluna D, de Alarcon PA, Schwartz CL (2006) APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer 46(3):320–324. doi:10.1002/pbc.20563
Windsor R, Stiller C, Webb D (2008) Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer 50(4):784–787. doi:10.1002/pbc.21293
Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 105(3):948–958. doi:10.1182/blood-2004-03-0973, 2004-03-0973 [pii]
Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, Kremens B, Lang P, Fuhrer M, Kuhne T, Parwaresch R, Ebell W, Reiter A (2006) Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents–a Berlin-Frankfurt-Munster group report. Br J Haematol 133(2):176–182. doi:10.1111/j.1365-2141.2006.06004.x, BJH6004 [pii]
Woessmann W, Zimmermann M, Lenhard M, Burkhardt B, Rossig C, Kremens B, Lang P, Attarbaschi A, Mann G, Oschlies I, Klapper W, Reiter A (2011) Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 29(22):3065–3071. doi:10.1200/JCO.2011.34.8417, JCO.2011.34.8417 [pii]
Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ, Yang WI, Lyu CJ (2006) Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology. Ann Hematol 85(11):787–794. doi:10.1007/s00277-006-0169-2
Wondergem MJ, Zijlstra JM, de Rooij M, Visser OJ, Huijgens PC, Zweegman S (2012) Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with (90) Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation. Br J Haematol 157(3):395–7. doi:10.1111/j.1365-2141.2011.08991.x
Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, Brugieres L, Le Deley MC (2011) Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer 56(7):1071–1077. doi:10.1002/pbc.22940
Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B (2005) Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 36(3):271–273. doi:10.1038/sj.bmt.1705036, 1705036 [pii]
Yahalom J, Ryu J, Straus DJ, Gaynor JJ, Myers J, Caravelli J, Clarkson BD, Fuks Z (1991) Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 9(12):2193–2201
Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O'Brien JP, Portlock CS, Straus DJ, Phillips J, Fuks Z (1993) Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 11(6):1062–1070
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012a) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30(18):2183–2189. doi:10.1200/JCO.2011.38.0410, JCO.2011.38.0410 [pii]
Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, Le Corre C, Shen A, Engert A (2012b) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 30(18):2197–2203. doi:10.1200/JCO.2011.38.1350, JCO.2011.38.1350 [pii]
Yu R, Chen G, Zhou C, Gao Z, Shi Y, Zhou X, Xie J, Liu H, Gong L (2012) Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas. Leukemia Res 36(9):1141–1146. doi:10.1016/j.leukres.2012.06.005
Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89(3):814–822
Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A, Popplewell L, Gaal K, Senitzer D, Kogut N, O'Donnell M, Forman SJ (2011) Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma 52(8):1463–1473. doi:10.3109/10428194.2011.574754
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157–163. doi:10.1038/nature10725, nature10725 [pii]
Zinzani PL, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M, Piccaluga PP, Tura S (2000) Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 85(9):926–929
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
O’Brien, M.M., Absalon, M.J., Gross, T.G., Kelly, K.M. (2014). Lymphomas. In: Smith, F., Reaman, G., Racadio, J. (eds) Hematopoietic Cell Transplantation in Children with Cancer. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39920-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-39920-6_10
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-39919-0
Online ISBN: 978-3-642-39920-6
eBook Packages: MedicineMedicine (R0)